Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Farment Bio Solutions Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is concentrated under 1 distinct examiner and 1 distinct art unit, indicating a highly focused prosecution footprint at this stage. The lack of distribution across multiple examiners suggests that the portfolio's current activity is limited to a specific technological niche or a single patent family, requiring a very targeted legal strategy.
KANE, TREVOR LOGAN is identified as the busiest examiner for the company, responsible for the 1 busiest examiner pending office action. Because this individual handles the entirety of the pending workload, the prosecution strategy for Farment Bio Solutions Ltd. is presently dependent on the specific tendencies and requirements of this one examiner. Practitioners should monitor this examiner's specific art unit practices, as the 1 distinct art unit involved will dictate the procedural framework for the company's current patent applications. This concentration of 1 pending office action under a single official means that the company's immediate patent outcomes are not diversified across different USPTO perspectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KANE, TREVOR LOGAN | 1 | 68.8% | +53.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17585952 | BIO-STIMULANT AND METHOD OF PRODUCING SAME | KANE, TREVOR LOGAN | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17585952 | BIO-STIMULANT AND METHOD OF PRODUCING SAME | KANE, TREVOR LOGAN | 1657 | §103 | Final Rejection | — | Pending | Jan 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFarment Bio Solutions Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Trevor Logan Kane has the most, with 1 of Farment Bio Solutions Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
